iX Biopharma Ltd. (SG:42C) has released an update.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
iX Biopharma Ltd. recently held its Annual General Meeting where key initiatives for growth were discussed, including the development of the GLP-1 Wafer, Wafermine, and the Healthspan Product SL-NAD+. The company emphasized its strategic focus on out-licensing opportunities and a commercial strategy for NAD+ to fast-track monetization. This strategic direction aims to boost shareholder value and enhance the company’s market positioning.
For further insights into SG:42C stock, check out TipRanks’ Stock Analysis page.